—
Price
—
Market Cap
—
P/E Ratio
—
Forward P/E
—
EPS (TTM)
—
Dividend Yield
—
Cash
—
Total Debt
—
Shares Out
Institutional Ownership of BIO-RAD LABORATORIES-A
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Longleaf Partners|Mason Hawkins
|
227.6K | $69M | — | — |
Trading Activity for BIO-RAD LABORATORIES-A
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q4 | |||||
| SELL | -4.1% | 227.6K | $69M | — | |
| 2025-Q3 | |||||
| SELL | -1.1% | 809.5K | $227M | — | |
| SELL | -24.8% | 237.3K | $67M | — | |
| 2025-Q2 | |||||
| BUY | +13.0% | 818.6K | $198M | — | |
| SELL | -2.6% | 315.3K | $76M | — | |
| 2025-Q1 | |||||
| BUY | +29.3% | 724.7K | $176M | — | |
| BUY | +5.0% | 323.8K | $79M | — | |
| 2024-Q4 | |||||
| BUY | +48.0% | 560.5K | $184M | — | |
| SELL | -3.1% | 308.5K | $101M | — | |
| 2024-Q3 | |||||
| BUY | +263.5% | 378.7K | $127M | — | |
| SELL | -2.0% | 318.3K | $107M | — | |
| 2024-Q2 | |||||
| SELL | -5.5% | 325.0K | $89M | — | |
| BUY | +60.1% | 104.2K | $28M | — | |
| 2024-Q1 | |||||
| SELL | -5.5% | 344.0K | $119M | — | |
| BUY | NEW | 65.1K | $23M | — | |
| 2023-Q4 | |||||
| BUY | +11.6% | 364.1K | $118M | — | |
| SELL | -1.1% | 4.5K | $1M | — | |
| 2023-Q3 | |||||
| BUY | +0.2% | 326.1K | $117M | — | |
| BUY | +3.1% | 4.5K | $2M | — | |
| 2023-Q2 | |||||
| BUY | NEW | 325.5K | $123M | — | |
| SELL | -86.2% | 4.4K | $2M | — | |
| 2023-Q1 | |||||
| SELL | -0.3% | 31.8K | $15M | — | |
| 2022-Q4 | |||||
| SELL | -52.1% | 31.9K | $13M | — | |
| 2022-Q3 | |||||
| BUY | +4.3% | 66.7K | $28M | — | |
| 2022-Q2 | |||||
| BUY | +3.5% | 63.9K | $32M | — | |
| 2022-Q1 | |||||
| BUY | +10.7% | 61.7K | $35M | — | |
| 2021-Q4 | |||||
| BUY | +7.3% | 55.8K | $42M | — | |
| 2021-Q3 | |||||
| SELL | -0.4% | 51.9K | $39M | — | |
| 2021-Q2 | |||||
| BUY | +1.6% | 52.1K | $34M | — | |
| 2021-Q1 | |||||
| BUY | +4.0% | 51.3K | $29M | — | |
| 2020-Q4 | |||||
| SELL | -23.4% | 49.3K | $29M | — | |
| 2020-Q3 | |||||
| SELL | -11.4% | 64.4K | $33M | — | |
| 2020-Q2 | |||||
| SELL | -54.2% | 72.7K | $33M | — | |
| 2020-Q1 | |||||
| SELL | -29.9% | 158.8K | $56M | — | |
| 2019-Q4 | |||||
| BUY | +1.0% | 226.5K | $84M | — | |
| 2019-Q3 | |||||
| SELL | -3.1% | 224.2K | $75M | — | |
| 2019-Q2 | |||||
| SELL | -3.8% | 231.3K | $72M | — | |
| 2019-Q1 | |||||
| BUY | +7.1% | 240.3K | $73M | — | |
| 2018-Q4 | |||||
| SELL | -3.6% | 224.3K | $52M | — | |
| 2018-Q3 | |||||
| BUY | +0.3% | 232.7K | $73M | — | |
| 2018-Q2 | |||||
| SELL | -7.6% | 232.0K | $67M | — | |
| 2018-Q1 | |||||
| SELL | -6.1% | 251.1K | $63M | — | |
Insider Trading for BIO-RAD LABORATORIES-A
No Insider Transactions
No Form 4 filings found for this stock in the last 2 years.